STAT6 and neoplasm: In an orthotopic model of HCC resistant to anti‐PD‐1 or anti‐CSF1R immunotherapies, systemic administration of ExoASO‐STAT6 also results in a potent anti‐tumor activity associated with a decrease in M2‐like markers as TGF‐β1 and Ccl17, an increase in the M1‐like marker IL‐1β, and an increase in interferon (IFN) and cytotoxic T‐cell gene signatures consistent with a reprogramming of the TME.108